STADA Arzneimittel, a big pharma company and Grünenthal GmbH have signed pharma deals contracts on the purchase of a branded product portfolio including the associated sales structures for numerous national markets in Central and Eastern Europe as well as in the Middle East.
The purchase price for the branded product portfolio including sales structures and various pipeline products amounts to a total of approx. EUR 360 million in cash as already announced in May.
The products are for the most part prescription drugs and positioned primarily in the pain area of indication.
The product portfolio to be acquired consists of over 14 own and licensed brands for Central and Eastern Europe as well as the Middle East.
The pharma deals acquisition requires the approval of the responsible anti-trust authorities, so that the implementation of the transaction, which was agreed today, and the consolidation of product sales is expected for the fourth quarter of 2011.
Payment of the purchase price will be made at the time of completion of the acquisition.
STADA will use cash on hand, free cash flow as well as existing free credit lines to finance the acquisition.
In addition, the placement of a further corporate bond is currently being examined in this context.
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity